Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 13/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 12/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.42 |
| ▸ | MTOR | P42345 | 6/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1359678 | 0.84 | LMNA (0.37) | PIK3CAPIK3R1PIK3CDPIK3CBMTOR | |
| SCHEMBL1680072 | 0.75 | PIK3CD (0.44) | PIK3CAPIK3R1PIK3CDPIK3CB | |
| SCHEMBL1680307 | 0.75 | PIK3CA (0.43) | PIK3CAPIK3R1PIK3CDPIK3CB | |
| SCHEMBL1680101 | 0.74 | LMNA (0.36) | PIK3CAPIK3R1PIK3CDPIK3CBMTOR | |
| SCHEMBL1680082 | 0.69 | PIK3R1 (0.53) | PIK3CAPIK3R1PIK3CDPIK3CB | |
| SCHEMBL1568776 | 0.67 | PIK3CA (0.42) | PIK3CAPIK3R1PIK3CDPIK3CBMTOR | |
| SCHEMBL15477581 | 0.66 | PIK3CD (0.62) | PIK3CAPIK3R1PIK3CDPIK3CBMTOR | |
| SCHEMBL1680092 | 0.61 | PIK3R1 (0.59) | PIK3CAPIK3R1PIK3CDPIK3CB | |
| SCHEMBL11961150 | 0.60 | PIK3CB (0.65) | PIK3CAPIK3R1PIK3CDPIK3CBMTOR | |
| SCHEMBL477346 | 0.60 | PIK3CB (1.00) | PIK3CAPIK3R1PIK3CDPIK3CBMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051699-A1 | PI3K (delta) SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2014-02-20 | — | — | US | claimed |
| US-8569296-B2 | PI3K (delta) selective inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-10-29 | — | — | US | claimed |
| US-20120202805-A1 | PI3K (delta) SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY, LLC | 2012-08-09 | — | — | US | claimed |
| US-20140051699-A1 | PI3K (delta) SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-8569296-B2 | PI3K (delta) selective inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120202805-A1 | PI3K (delta) SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY, LLC | 2012-08-09 | — | — | US | disclosed |
| EP-2483272-A2 | PI3K (DELTA) SELECTIVE INHIBITORS | Xcovery Holding Company LLC (US) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011041399-A2 | PI3K (DELTA) SELECTIVE INHIBITORS | TYROGENEX, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051699-A1 | PI3K (delta) SELECTIVE INHIBITORS | PIK3CD, PIK3CA, PIK3R5 | PIK3CA 2/4885PIK3R1 10/4885PIK3CD 1/4885 |
| US-20120202805-A1 | PI3K (delta) SELECTIVE INHIBITORS | PIK3CD, PIK3CA, PIK3R5 | PIK3CA 2/4885PIK3R1 10/4885PIK3CD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.